Skip to main content

Table 4 Quality of life scores of the control and intervention group at baseline and 12 months follow-up, and the change over 12 months

From: Cost-utility of medication withdrawal in older fallers: results from the improving medication prescribing to reduce risk of FALLs (IMPROveFALL) trial

  Group N Baseline Follow-up p-values* Change p-values**
EQ-5D utility score Control 263 0.78 ± 0.22 0.74 ± 0.25 0.01 −0.04 ± 0.22 0.02
  Intervention 285 0.74 ± 0.26 0.75 ± 0.26 0.75 0.01 ± 0.24  
SF-12 PCS score Control 258 46.2 ± 9.9 42.2 ± 11.6 <0.01 −3.9 ± 8.5 0.08
  Intervention 283 45.6 ± 9.5 43.0 ± 10.7 <0.01 −2.6 ± 8.5  
SF-12 MCS score Control 258 53.2 ± 9.0 52.5 ± 9.2 0.28 −0.7 ± 9.7 0.90
  Intervention 283 53.3 ± 9.5 52.5 ± 9.0 0.20 −0.8 ± 9.7  
  1. Data are given as mean values ± standard deviation
  2. 9 and 23 participants in the control and intervention group declined or were unable to complete EQ-5D questionnaires after 12-months follow-up, an additional 5 and 2 participants in the control and intervention group had incomplete SF-12 questionnaires after 12-months follow-up
  3. *Wilcoxon Signed Rank test (comparing baseline and follow-up)
  4. **Two-way ANOVA of the change over 12 months